Navigation Links
DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study
Date:8/2/2010

CLEVELAND, Aug. 2 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that DAIICHI SANKYO EUROPE GmbH has selected DATATRAK's eClinical™ platform for a cardiovascular clinical study encompassing 80 sites and 1,200 patients across Europe. Reaping the benefits of a unified platform, DAIICHI SANKYO EUROPE GmbH will utilize DATATRAK's Electronic Data Capture solution in addition to web-based Patient Randomization, Drug Inventory Management, Lab Import and Auto-Coding Engine solutions. Also, study users will be able to view, manage and report on patient data via DATATRAK's dynamic, ad-hoc reporting module. As with all studies for this sponsor, DATATRAK will be producing CDISC SDTM compliant exports throughout the study.

"We have decided to use DATATRAK because the unified platform appealed to our needs. The ease in which for example IWRS or study drug management can be utilized with EDC within one solution will bring us significant benefit throughout the study. Furthermore, the built-in data export routines to SDTM and flexible ad-hoc reporting tools supporting our efforts in process control," said Paul-Egbert Reimitz, Director of Biostatistics and Data Operations at DAIICHI SANKYO EUROPE GmbH.

"We are delighted to have been awarded this new study by DAIICHI SANKYO EUROPE, whose adoption of DATATRAK ONE™ is a testament to both teams' hard work and success in implementing complex international clinical trials," said Laurence P. Birch, DATATRAK's Chairman of the Board. "We remain focused on providing our clients the benefits of increased patient safety, real-time data availability and management in addition to a completely unified user experience, ranging from investigative sites to Sponsors and CROs."

About DAIICHI SANKYO

DAIICHI SANKYO is a global pharmaceutical company that focuses on research and the marketing of innovative medications. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. With net sales of nearly euro 7.3 billion in fiscal year 2009 (as at March 31st), DAIICHI SANKYO is one of the world's 20 leading pharmaceutical companies. The company's world headquarters is in Tokyo. Its European base is located in Munich. DAIICHI SANKYO has affiliates in 12 European countries, and one of its global manufacturing sites is located in Pfaffenhofen, a town in the German state of Bavaria. The company's research activities focus on the areas of cardiovascular diseases, hematology, anti-infectives and cancer. Its aim is to develop medications that are best in their class or create a new class of active ingredients.

For more information, please visit: http://www.daiichi-sankyo.eu.

About DATATRAK International, Inc.

DATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. DATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery in DATATRAK ONE™, the seamless delivery of product and services. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The DATATRAK eClinical™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, has successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK has offices located in Cleveland, Ohio, and Bryan, Texas.

For more information, visit http://www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially for those contemplated in these forward looking statements please see the Company's press release filed March 31, 2010 announcing its fourth quarter and full year results for 2009. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE DATATRAK International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
2. Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs
3. Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index
4. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
5. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
6. ApoA-I Data Presented at European Society of Cardiology Congress
7. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
8. CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
9. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. Kuvan Receives Positive Opinion From CHMP for European Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... As part ... the series will explore the laboratory testing for DIC in order to illuminate this ... disorder which can occur in hospitalized patients resulting in a high degree of morbidity ...
(Date:4/25/2017)... ... 25, 2017 , ... Covalent Metrology has two ... unit provides high-quality data to clients, both faster and cheaper than competing ... are no price premiums, and customers are welcome to participate in the measurements ...
(Date:4/21/2017)... ... April 21, 2017 , ... Having worked on the design ... is pleased to introduce it to top lab design architects from around the country ... and VP of Industrial Design and Engineering Greg Casey will be at the show, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick ... a range of emerging technology-based businesses, recently earned a $77,518 grant from the ... , Founded in 2004, FITCI is Frederick’s first incubator. A non-profit corporation, FITCI ...
Breaking Biology Technology:
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/22/2017)... NEW YORK , March 21, 2017 /PRNewswire/ ... Customer Marketing Cloud used by retailers such as ... in its platform — Product Recommendations and Replenishment. Using ... to give more personalized product and replenishment recommendations ... purchases, but also on predictions of customer intent ...
Breaking Biology News(10 mins):